Endologix Inc. (ELGX)

4.32
NASDAQ : Health Technology
Prev Close 4.21
Day Low/High 4.17 / 4.34
52 Wk Low/High 3.77 / 7.66
Avg Volume 604.40K
Exchange NASDAQ
Shares Outstanding 83.45M
Market Cap 351.34M
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Endologix Appoints Greg Morrow As Chief Marketing Officer And Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Endologix Appoints Greg Morrow As Chief Marketing Officer And Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that it has appointed Greg Morrow as the Company's Chief Marketing Officer, effective immediately.

Endologix, Inc. To Announce Fourth Quarter And Fiscal Year 2017 Financial Results On February 21, 2018

Endologix, Inc. To Announce Fourth Quarter And Fiscal Year 2017 Financial Results On February 21, 2018

Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the fourth quarter and fiscal year 2017 after the market...

Endologix Becomes Oversold (ELGX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Endologix, Inc. To Present At The J.P. Morgan Healthcare Conference

Endologix, Inc. To Present At The J.P. Morgan Healthcare Conference

Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, will present...

Endologix Reaches Analyst Target Price

In recent trading, shares of Endologix Inc. have crossed above the average analyst 12-month target price of $5.33, changing hands for $5.39/share.

Endologix, Inc. To Present At The Piper Jaffray 29th Annual Healthcare Conference

Endologix, Inc. To Present At The Piper Jaffray 29th Annual Healthcare Conference

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John McDermott, Chief Executive Officer, will present at the Piper Jaffray 29 th Annual Healthcare...

Endologix Reports Third Quarter 2017 Financial Results

Endologix Reports Third Quarter 2017 Financial Results

Endologix, Inc. (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the third quarter ended September 30, 2017.

ELGX Crosses Above Average Analyst Target

In recent trading, shares of Endologix Inc. have crossed above the average analyst 12-month target price of $5.70, changing hands for $5.92/share.

Endologix Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Endologix Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Endologix, Inc. (Nasdaq:ELGX) ("Endologix"), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of inducement equity awards to its newly appointed Chief Operating...

Endologix, Inc. To Present At The Stifel 2017 Healthcare Conference

Endologix, Inc. To Present At The Stifel 2017 Healthcare Conference

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, will present...

Endologix Appoints John Onopchenko As Chief Operating Officer

Endologix Appoints John Onopchenko As Chief Operating Officer

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that it has appointed John Onopchenko as the Company's Chief Operating Officer, effective October...

Short Interest In Endologix Drops 12.2%

Short Interest In Endologix Drops 12.2%

The most recent short interest data has been released for the 09/29/2017 settlement date, which shows a 1,880,477 share decrease in total short interest for Endologix Inc. , to 13,525,718, a decrease of 12.21% since 09/15/2017.

Endologix, Inc. To Announce Third Quarter 2017 Financial Results On November 7, 2017

Endologix, Inc. To Announce Third Quarter 2017 Financial Results On November 7, 2017

Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the third quarter of fiscal year 2017 after the market...

Endologix Receives IDE Approval For The EVAS2 Confirmatory Clinical Study To Evaluate The Nellix® EndoVascular Aneurysm Sealing System

Endologix Receives IDE Approval For The EVAS2 Confirmatory Clinical Study To Evaluate The Nellix® EndoVascular Aneurysm Sealing System

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that it has received Investigational Device Exemption ("IDE") approval from the United States...

Endologix Announces CE Mark Approval For The Nellix® EndoVascular Aneurysm Sealing System With The Refined Indications For Use

Endologix Announces CE Mark Approval For The Nellix® EndoVascular Aneurysm Sealing System With The Refined Indications For Use

Endologix, Inc. (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced the CE Mark approval for its Nellix ® EndoVascular Aneurysm Sealing System ("Nellix") with the...

Endologix Announces Collaboration Agreements With Japan Lifeline For The Development And Commercialization Of Thoracic Endovascular Systems In Japan

Endologix Announces Collaboration Agreements With Japan Lifeline For The Development And Commercialization Of Thoracic Endovascular Systems In Japan

Endologix, Inc. (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it has signed a joint research and development agreement, as well as an exclusive distribution...

Endologix Announces Positive Clinical Results From The LEOPARD Clinical Study

Endologix Announces Positive Clinical Results From The LEOPARD Clinical Study

Endologix, Inc. (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced positive interim results from the LEOPARD ( Looking at  Evar  Outcomes...

Endologix Reports Second Quarter 2017 Financial Results

Endologix Reports Second Quarter 2017 Financial Results

Endologix, Inc. (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the second quarter ended June 30, 2017.

Interesting ELGX Call Options For February 2018

Interesting ELGX Call Options For February 2018

Investors in Endologix Inc. saw new options become available this week, for the February 2018 expiration.

Endologix, Inc. To Announce Second Quarter 2017 Financial Results On August 2, 2017

Endologix, Inc. To Announce Second Quarter 2017 Financial Results On August 2, 2017

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the second quarter of fiscal year 2017 after the market...

Endologix, Inc. To Present At The Canaccord Genuity 37th Annual Growth Conference

Endologix, Inc. To Present At The Canaccord Genuity 37th Annual Growth Conference

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, will present...

Endologix Presents Positive Two-Year Clinical Data From The Nellix® EVAS FORWARD IDE Trial

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced the presentation of two-year clinical data from the Company's Nellix® EVAS FORWARD IDE trial that...

Endologix Reports Positive Clinical Data From The Ovation LUCY Study

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced 30-day results from the LUCY (Evaluation of Fema Les who are Underrepresented Candidates for Abdominal...

TheStreet Quant Rating: D (Sell)